Literature DB >> 2967855

Hemodynamic, renal and endocrine effects of atrial natriuretic peptide infusion in severe heart failure.

C R Molina1, M B Fowler, S McCrory, C Peterson, B D Myers, J S Schroeder, F Murad.   

Abstract

The cardiac release and total body and renal clearances and the hemodynamic, renal and endocrine effects of increasing doses of atrial natriuretic peptide were investigated in 12 patients with severe chronic congestive heart failure. Immunoreactive arterial plasma levels of atrial natriuretic peptide were 10-fold higher than normal and there was no correlation between aortic atrial natriuretic peptide and cardiac filling pressures. The heart released atrial natriuretic peptide into the coronary sinus. The kidney, though a major clearance site, accounted for only 33% of the total body clearance. Administration of 0.3 micrograms/kg per min atrial natriuretic peptide produced significant changes in heart rate (95 +/- 4 to 85 +/- 4 beats/min) and mean arterial (92 +/- 8 to 77 +/- 9 mm Hg), right atrial (13 +/- 3 to 8 +/- 2 mm Hg) and mean pulmonary artery occluded (27 +/- 3 to 14 +/- 3 mm Hg) pressures. Atrial natriuretic peptide increased cardiac index (2.25 +/- 0.18 to 2.83 +/- 0.3 liters/min per m2) and stroke work index (21 +/- 1.5 to 29 +/- 3.4 g/m2), whereas systemic vascular resistance (1,424 +/- 139 to 1,033 +/- 97 dynes.s.cm(-5)) decreased. Infusion of 0.1 microgram/kg per min atrial natriuretic peptide increased urinary flow 128%, fractional excretion of sodium 133% and fractional excretion of potassium 35%. The filtration fraction increased from 29 +/- 2 to 31 +/- 4%. This represented a disproportionate rise in glomerular filtration rate over renal plasma flow. Plasma aldosterone and norepinephrine decreased whereas plasma renin activity remained unchanged. In association with these hemodynamic, excretory and endocrine changes, the urinary excretion of cyclic guanosine monophosphate doubled. Placebo had no effect. These results showed that, despite high circulating levels of atrial natriuretic peptide, administration of this hormone in heart failure is associated with potentially beneficial hemodynamic, renal and endocrine effects.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2967855     DOI: 10.1016/0735-1097(88)90371-3

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  10 in total

1.  Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt.

Authors:  Takahiro Kato; John Muraski; Yan Chen; Yasuyuki Tsujita; Jason Wall; Christopher C Glembotski; Erik Schaefer; Mary Beckerle; Mark A Sussman
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 2.  Outpatient management of congestive heart failure.

Authors:  E K Massin
Journal:  Tex Heart Inst J       Date:  1998

Review 3.  Molecular Mechanism of Induction of Bone Growth by the C-Type Natriuretic Peptide.

Authors:  Estera Rintz; Grzegorz Węgrzyn; Toshihito Fujii; Shunji Tomatsu
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

4.  Hemodynamic and humoral effects of atrial natriuretic peptide on pulmonary circulation after cardiac surgery.

Authors:  Keisuke Morimoto; Iwao Taniguchi; Shigeto Miyasaka; Shingo Ishiguro; Shigetsugu Ohgi
Journal:  Surg Today       Date:  2008-04-30       Impact factor: 2.549

Review 5.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

6.  Increased circulating atrial natriuretic factor concentrations in patients with chronic heart failure after inhibition of neutral endopeptidase: effects on diastolic function.

Authors:  D B Northridge; A Jardine; E Henderson; S G Dilly; H J Dargie
Journal:  Br Heart J       Date:  1992-10

7.  Comparison of the efficacy of recombinant human brain natriuretic peptide with saline hydration in preventing contrast-induced nephropathy in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention.

Authors:  Chaoyu Sun; Jixin Zhi; Xiaopeng Bai; Xueqi Li; Hongyuan Xia
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 8.  Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy.

Authors:  Javier Díez
Journal:  Eur J Heart Fail       Date:  2016-10-21       Impact factor: 15.534

Review 9.  Phase-contrast magnetic resonance imaging to assess renal perfusion: a systematic review and statement paper.

Authors:  Giulia Villa; Steffen Ringgaard; Ingo Hermann; Rebecca Noble; Paolo Brambilla; Dinah S Khatir; Frank G Zöllner; Susan T Francis; Nicholas M Selby; Andrea Remuzzi; Anna Caroli
Journal:  MAGMA       Date:  2019-08-17       Impact factor: 2.310

10.  Efficacy and Safety of 1-Hour Infusion of Recombinant Human Atrial Natriuretic Peptide in Patients With Acute Decompensated Heart Failure: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.

Authors:  Guogan Wang; Pengbo Wang; Yishi Li; Wenxian Liu; Shugong Bai; Yang Zhen; Dongye Li; Ping Yang; Yu Chen; Lang Hong; Jianhui Sun; Junzhu Chen; Xian Wang; Jihong Zhu; Dayi Hu; Huimin Li; Tongguo Wu; Jie Huang; Huiqiong Tan; Jian Zhang; Zhongkai Liao; Litian Yu; Yi Mao; Shaodong Ye; Lei Feng; Yihong Hua; Xinhai Ni; Yuhui Zhang; Yang Wang; Wei Li; Xiaojun Luan; Xiaolu Sun; Sijia Wang
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.